Cambridge Cognition Holdings PLC - Cambridge, England-based technology company developing digital health products to better understand, detect and treat conditions affecting brain health - Wins two contracts worth £2.1 million to provide its CANTAB cognitive assessments and electronic Clinical Outcome Assessments for two trials involving patients ‘with a rare disease’. Says that the contracts have been awarded by a new customer, and expects revenues to be recognised over the next five years.
Chief Executive Office Matthew Stork says: ‘These contracts will strengthen our presence in the rare disease field and showcase how our cognitive assessments can be used effectively in the development of symptom modifying treatments.’
Current stock price: 101.74 pence, up 5.4% in London on Wednesday afternoon
12 month change: down 37%
Copyright 2023 Alliance News Ltd. All Rights Reserved.
